Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment

scientific article published on 23 February 2005

Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1034653442
P356DOI10.1007/S00296-004-0571-9
P698PubMed publication ID15726373

P50authorNicola MartinelliQ42699987
P2093author name stringPaola Caramaschi
Alessandro Volpe
Antonio Carletto
Domenico Biasi
Lisa Maria Bambara
Sara Pieropan
Elisabetta Tonolli
P2860cites workCitrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodiesQ24564876
C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunityQ24675774
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisQ27860872
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupQ29616063
Review article: safety of infliximab in clinical trialsQ33793931
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study GroupQ33885648
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trialsQ33925623
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapyQ33973488
Clinical utility of the anti-CCP assay in patients with rheumatic diseasesQ35553110
Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.Q40569388
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritisQ42631739
Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE).Q43659678
A lupus-like syndrome associated with infliximab therapyQ44469108
Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis.Q44511565
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisQ44541019
Citrullination of synovial proteins in murine models of rheumatoid arthritisQ44586791
High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritisQ44661580
Infliximab-induced lupus in Crohn's disease: a case report.Q44692619
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptideQ44791267
Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritisQ46376254
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort studyQ47771380
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathyQ49031401
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunityQ56595317
Anti-TNF-alpha-induced systemic lupus syndromeQ73046347
Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab)Q73168489
Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodiesQ73202398
Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritisQ73249154
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trialQ73775013
Etanercept-induced subacute cutaneous lupus erythematosusQ77174829
In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTLQ77337880
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisQ77341367
Drug-induced systemic lupus erythematosus associated with etanercept therapyQ77696979
Drug-induced systemic lupus erythematosus and TNF-alpha blockersQ94077789
P433issue1
P921main subjectrheumatoid arthritisQ187255
P304page(s)58-62
P577publication date2005-02-23
P1433published inRheumatology InternationalQ15763689
P1476titleAntibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment
P478volume26

Reverse relations

cites work (P2860)
Q35207886A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis
Q34896439Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study
Q44830835Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis
Q35475541Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis
Q43195995Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis
Q24627677Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies
Q35645491Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis
Q24675281Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review
Q35760039High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis
Q36733774Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris
Q44343787Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
Q35741161Insights to clinical use of serial determination in titers of cyclic citrullinated peptide autoantibodies
Q90176726Key Components of the Complement Lectin Pathway Are Not Only Required for the Development of Inflammatory Arthritis but Also Regulate the Transcription of Factor D
Q79736443Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis
Q40329877Pathogenic role of antibodies to citrullinated proteins in rheumatoid arthritis
Q86848982Psoriatic arthritis
Q37353700Rheumatoid factors: clinical applications
Q83081026Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis
Q47615878Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis
Q37280952The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases
Q35636615The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis
Q27022645The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses